Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Burchert

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Cancer Research|April 14, 2011
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemiaXiaolin Hu, Dafeng Yang, Mary Zimmerman, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2019
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trialLaura Budau, Christian Wilhelm, Roland Moll, et al.
Cancers|March 6, 2021
IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML CellsFranziska Liss, Miriam Frech, Ying Wang, et al.
Oncoimmunology|May 4, 2018
High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusionVerena Nilius, Madeleine C Killer, Nina Timmesfeld, et al.
Leukemia|June 20, 2020
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Thomas Wiesmann, Claus F Vogelmeier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 23, 2022
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidenceMaximilian J Reinecke, Gerrit Ahlers, Andreas Burchert, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Blood|December 6, 2003
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2Andreas Burchert, Dali Cai, Lorenz C Hofbauer, et al.
Journal of Hematology & Oncology|July 10, 2019
Nuclear factor of activated T-cells, NFATC1, governs FLT3<sup>ITD</sup>-driven hematopoietic stem cell transformation and a poor prognosis in AMLMaria Solovey, Ying Wang, Christian Michel, et al.
Blood|October 24, 2002
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaAndreas Burchert, Stefan Wölfl, Manuel Schmidt, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Cancer Research|April 14, 2011
IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemiaXiaolin Hu, Dafeng Yang, Mary Zimmerman, et al.
Journal of Cancer Research and Clinical Oncology|July 6, 2019
Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trialLaura Budau, Christian Wilhelm, Roland Moll, et al.
Cancers|March 6, 2021
IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML CellsFranziska Liss, Miriam Frech, Ying Wang, et al.
Oncoimmunology|May 4, 2018
High β-1,4-Galactosyltransferase-I expression in peripheral T-lymphocytes is associated with a low risk of relapse in germ-cell cancer patients receiving high-dose chemotherapy with autologous stem cell reinfusionVerena Nilius, Madeleine C Killer, Nina Timmesfeld, et al.
Leukemia|June 20, 2020
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)Andreas Neubauer, Thomas Wiesmann, Claus F Vogelmeier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 23, 2022
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidenceMaximilian J Reinecke, Gerrit Ahlers, Andreas Burchert, et al.
Acta Haematologica|May 5, 2025
Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trialPhilipp le Coutre, Andreas Burchert, Susanne Saußele, et al.
Blood|December 6, 2003
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2Andreas Burchert, Dali Cai, Lorenz C Hofbauer, et al.
Journal of Hematology & Oncology|July 10, 2019
Nuclear factor of activated T-cells, NFATC1, governs FLT3<sup>ITD</sup>-driven hematopoietic stem cell transformation and a poor prognosis in AMLMaria Solovey, Ying Wang, Christian Michel, et al.
Blood|October 24, 2002
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemiaAndreas Burchert, Stefan Wölfl, Manuel Schmidt, et al.
Pageof 11